Aravindhan Veerapandiyan, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Biogen, Novartis, AveXis, Sarepta therapeutics, PTC therapeutics, Scholar Rock, Fibrogen, AMO pharma, Pfizer, Edgewise therapeutics
    Topic:
    Ad Hoc Advisory boards
    Date added:
    12/22/2022
    Date updated:
    12/18/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Sarepta, Fibrogen, Pfizer, Octapharma, Regenxbio, Edgewise therapeutics, Amgen, Lilly, Teva therapeutics, Impax, Capricor therapeutics, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and France Foundation
    Topic:
    Research / Grant Support
    Date added:
    12/22/2022
    Date updated:
    12/18/2023
Return to 45th Annual Carrell Krusen Neuromuscular Symposium (RP2302A)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.